retatrutide phase 2 trial results Dosage & Titration: Complete Escalation Protocol (5-30 mg) Retatrutide: A Promising Option for

24% of GLP-1 users have booked a trip to celebrate a weight loss milestone

Patients whose coverage changes mid-treatment face difficult decisions about continuing at higher out-of-pocket cost, switching to compounded versions, or stopping prematurely

Phase 2 results (48 weeks, published in NEJM) The landmark Phase 2 trial randomized 338 participants across multiple dose groups

More importantly for muscle-focused applications, the proportion of lean mass loss to total weight loss was similar to or better than other obesity treatments, with Retatrutide demonstrating significant improvements in total body fat mass reduction compared to both placebo and dulaglutide (a single-receptor GLP-1 agonist)

It connects patients with licensed providers for GLP-1 prescriptions while prioritizing transparency and patient education

Find articles by Singh, A